New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency

References

• JanciauskieneSM, BalsR, KoczullaR, VogelmeierC, KohnleinT, WelteT. The discovery of alpha1-antitrypsin and its role in health and disease. Respir Med. 2011;105(8):1129–1139.21367592
   PubMed Web of Science ®Google Scholar
• FairbanksKD, TavillAS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol. 2008;103(8):2136–2141. doi:10.1111/ajg.2008.103.issue-818796107
   PubMed Web of Science ®Google Scholar
• GrossB, GrebeM, WenckerM, StollerJK, BjurstenLM, JanciauskieneS. New findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy. Dermatology. 2009;218(4):370–375. doi:10.1159/00020298219218787
   PubMed Web of Science ®Google Scholar
• ElzoukiAN, SegelmarkM, WieslanderJ, ErikssonS. Strong link between the alpha 1-antitrypsin PiZ allele and Wegener’s granulomatosis. J Intern Med. 1994;236(5):543–548. doi:10.1111/j.1365-2796.1994.tb00842.x7964431
   PubMed Web of Science ®Google Scholar
• KöhnleinT, JanciauskieneS, WelteT. Diagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiency. Ther Adv Respir Dis. 2010;4(5):279–287. doi:10.1177/175346581037640720660539
   PubMedGoogle Scholar
• Chorostowska-WynimkoJ. Disease modification in emphysema related to alpha-1 antitrypsin deficiency. COPD. 2016;13(6):807–815. doi:10.1080/15412555.2016.117822427172295
   PubMedGoogle Scholar
• McElvaneyNG, BurdonJ, HolmesM, et al. Long-term efficacy and safety of alpha1 proteinase inhibitor treatment for emphysema caused by severe alpha1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med. 2017;5(1):51–60. doi:10.1016/S2213-2600(16)30430-127916480
   PubMed Web of Science ®Google Scholar
• CraigTJ. Suspecting and testing for alpha-1 antitrypsin deficiency-an allergist’s and/or immunologist’s perspective. J Allergy Clin Immunol Pract. 2015;3(4):506–511. doi:10.1016/j.jaip.2015.04.00526032475
   PubMed Web of Science ®Google Scholar
• StrangeC, StollerJK, SandhausRA, DicksonR, TurinoG. Results of a survey of patients with alpha-1 antitrypsin deficiency. Respiration. 2006;73(2):185–190. doi:10.1159/00008806116141711
   PubMed Web of Science ®Google Scholar
• HorvathI, CanotilhoM, ChlumskyJ, et al. Diagnosis and management of alpha1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Res. 2019;5(1). doi:10.1183/23120541.00171-2018
   PubMedGoogle Scholar
• MiravitllesM, HerrC, FerrarottiI, et al. Laboratory testing of individuals with severe alpha1-antitrypsin deficiency in three European centres. Eur Respir J. 2010;35(5):960–968. doi:10.1183/09031936.0006970920436173
   PubMed Web of Science ®Google Scholar
• TejwaniV, SandersC, FyeE, NowackiA, StollerJ. Symptom and airflow correlates of delayed diagnosis in alpha-1 antitrypsin deficiency. Chest. 2017;152(4):A817. doi:10.1016/j.chest.2017.08.848
   Web of Science ®Google Scholar
• EsquinasC, BarrechegurenM, SucenaM, RodriguezE, FernandezS, MiravitllesM. Practice and knowledge about diagnosis and treatment of alpha-1 antitrypsin deficiency in Spain and Portugal. BMC Pulm Med. 2016;16(1):64. doi:10.1186/s12890-016-0222-4
   Web of Science ®Google Scholar
• GreulichT, OttavianiS, BalsR, et al. Alpha1-antitrypsin deficiency - diagnostic testing and disease awareness in Germany and Italy. Respir Med. 2013;107(9):1400–1408. doi:10.1016/j.rmed.2013.04.02323786890
   PubMed Web of Science ®Google Scholar
• Calle RubioM, SorianoJB, Lopez-CamposJL, et al. Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: a multilevel, cross-sectional analysis of the EPOCONSUL study. PLoS One. 2018;13(6):e0198777. doi:10.1371/journal.pone.019877729953442
   PubMed Web of Science ®Google Scholar
• SorianoJB, LucasSJ, JonesR, et al. Trends of testing for and diagnosis of alpha1-antitrypsin deficiency in the UK: more testing is needed. Eur Respir J. 2018;52(1). doi:10.1183/13993003.00360-2018
   Web of Science ®Google Scholar
• GreulichT, NellC, HerrC, VogelmeierC, KotkeV, WiedmannS, et al. Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003-2015. Orphanet J Rare Dis. 2016;11(1):75.27282198
   PubMed Web of Science ®Google Scholar
• MiravitllesM, DirksenA, FerrarottiI, et al. European respiratory society statement: diagnosis and treatment of pulmonary disease in alpha1-antitrypsin deficiency. Eur Respir J. 2017;50:5. doi:10.1183/13993003.00610-2017
   Web of Science ®Google Scholar
• GreulichT, VogelmeierCF. Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis. Ther Adv Respir Dis. 2016;10(1):72–84. doi:10.1177/175346581560216226341117
   PubMed Web of Science ®Google Scholar
• LuisettiM, Balfour-LynnIM, JohnsonSR, et al. Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. Respir Med. 2012;106(6):759–768. doi:10.1016/j.rmed.2012.02.01622414566
   PubMed Web of Science ®Google Scholar
• SeersholmN, WenckerM, BanikN, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J. 1997;10(10):2260–2263. doi:10.1183/09031936.97.101022609387950
   PubMed Web of Science ®Google Scholar
• PerkinsJT, ChoateR, ManninoDM, BrowningSR, SandhausRA. Benefits among patients with alpha-1 antitrypsin deficiency enrolled in a disease management and prevention program. Chronic Obstr Pulm Dis. 2016;4(1):56–64. doi:10.15326/jcopdf.4.1.2016.016128848911
   PubMed Web of Science ®Google Scholar
• CamposMA, AlazemiS, ZhangG, WannerA, SandhausRA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD. 2009;6(1):31–40. doi:10.1080/1541255080260741019229706
   PubMedGoogle Scholar
• CamposMA, RunkenMC, DavisAM, JohnsonMP, StoneGA, BuikemaAR. Impact of a health management program on healthcare outcomes among patients on augmentation therapy for alpha 1-antitrypsin deficiency: an insurance claims analysis. Adv Ther. 2018;35(4):467–481. doi:10.1007/s12325-018-0690-429616482
   PubMed Web of Science ®Google Scholar
• StockleyRA, MiravitllesM, VogelmeierC; Alpha One International R. Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis. 2013;8:149. doi:10.1186/1750-1172-8-14924063809
   PubMed Web of Science ®Google Scholar
• HumbertM, WagnerTO. Rare respiratory diseases are ready for primetime: from rare disease day to the European reference networks. Eur Respir J. 2017;49:2. doi:10.1183/13993003.00085-2017
   Web of Science ®Google Scholar
• European Reference Networks. ERN-LUNG cross-border referral operational. Available from: https://ern-lung.eu/inhalt/wp-content/uploads/2019/07/Cross-border-referral-operational.pdf. Accessed 129, 2019.
   Google Scholar
• Commission implementing decision (EU) 2019/1269 of 26 July 2019 amending implementing decision 2014/287/EU setting out criteria for establishing and evaluating European reference networks and their members and for facilitating the exchange of information and expertise on establishing and evaluating such networks. C/2019/5470. Official Journal of the European Union. L 200, 29.7.2019; 35–43. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32019D1269&from=EN. Accessed 129, 2019.
   Google Scholar
• KueppersF, SandersC. State-of-the-art testing for alpha-1 antitrypsin deficiency. Allergy Asthma Proc. 2017;38(2):108–114. doi:10.2500/aap.2017.38.403128120746
   PubMed Web of Science ®Google Scholar
• SandersCL, PonteA, KueppersF. The effects of inflammation on alpha 1 antitrypsin levels in a national screening cohort. COPD. 2018;15(1):10–16. doi:10.1080/15412555.2017.140160029381093
   PubMedGoogle Scholar
• American Thoracic S; European Respiratory S. American Thoracic Society/European respiratory society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900.14522813
   PubMed Web of Science ®Google Scholar
• FerrarottiI, ThunGA, ZorzettoM, et al. Serum levels and genotype distribution of alpha1-antitrypsin in the general population. Thorax. 2012;67(8):669–674. doi:10.1136/thoraxjnl-2011-20132122426792
   PubMed Web of Science ®Google Scholar
• BornhorstJA, ProcterM, MeadowsC, AshwoodER, MaoR. Evaluation of an integrative diagnostic algorithm for the identification of people at risk for alpha1-antitrypsin deficiency. Am J Clin Pathol. 2007;128(3):482–490. doi:10.1309/44J4KBCFQ8E9D1B817709323
   PubMed Web of Science ®Google Scholar
• SilvaD, OliveiraMJ, GuimaraesM, LimaR, GomesS, SeixasS. Alpha-1-antitrypsin (SERPINA1) mutation spectrum: three novel variants and haplotype characterization of rare deficiency alleles identified in Portugal. Respir Med. 2016;116:8–18. doi:10.1016/j.rmed.2016.05.00227296815
   PubMed Web of Science ®Google Scholar
• LuisettiM, FerrarottiI, CordaL, et al. Italian registry of patients with alpha-1 antitrypsin deficiency: general data and quality of life evaluation. COPD. 2015;12(Suppl 1):52–57. doi:10.3109/15412555.2015.102339325938293
   PubMedGoogle Scholar
• CordaL, MedicinaD, La PianaGE, et al. Population genetic screening for alpha1-antitrypsin deficiency in a high-prevalence area. Respiration. 2011;82(5):418–425. doi:10.1159/00032506721474916
   PubMed Web of Science ®Google Scholar
• GrahamRP, DinaMA, HoweSC, et al. SERPINA1 full-gene sequencing identifies rare mutations not detected in targeted mutation analysis. J Mol Diagn. 2015;17(6):689–694. doi:10.1016/j.jmoldx.2015.07.00226321041
   PubMed Web of Science ®Google Scholar
• KueppersF, AndrakeMD, XuQ, DunbrackRL Jr, KimJ, SandersCL. Protein modeling to assess the pathogenicity of rare variants of SERPINA1 in patients suspected of having alpha 1 antitrypsin deficiency. BMC Med Genet. 2019;20(1):125. doi:10.1186/s12881-019-0852-531307431
   PubMed Web of Science ®Google Scholar
• EndrullatC, GloklerJ, FrankeP, FrohmeM. Standardization and quality management in next-generation sequencing. Appl Transl Genom. 2016;10:2–9. doi:10.1016/j.atg.2016.06.00127668169
   PubMedGoogle Scholar
• MiravitllesM, Chorostowska-WynimkoJ, FerrarottiI, et al. The European Alpha-1 Research Collaboration (EARCO): a new ERS clinical research collaboration to promote research in alpha-1 antitrypsin deficiency. Eur Respir J. 2019;53(2):1900138. doi:10.1183/13993003.00138-201930765486
   PubMed Web of Science ®Google Scholar
• LaurellCB, SvegerT. Mass screening of newborn Swedish infants for alpha antitrypsin deficiency. Am J Hum Genet. 1975;27(2):213–217.1079113
   PubMed Web of Science ®Google Scholar
• MostafaviB, PiitulainenE, TanashHA. Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43–45 years. Int J Chron Obstruct Pulmon Dis. 2019;14:525–530. doi:10.2147/COPD.S18320530880942
   PubMed Web of Science ®Google Scholar
• SeersholmN, Kok-JensenA, DirksenA. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax. 1994;49(7):695–698. doi:10.1136/thx.49.7.6958066566
   PubMed Web of Science ®Google Scholar
• SeersholmN, Kok-JensenA. Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency. Thorax. 1998;53(4):265–268. doi:10.1136/thx.53.4.2659741368
   PubMed Web of Science ®Google Scholar
• PiitulainenE, TornlingG, ErikssonS. Environmental correlates of impaired lung function in non-smokers with severe alpha 1-antitrypsin deficiency (PiZZ). Thorax. 1998;53(11):939–943. doi:10.1136/thx.53.11.93910193391
   PubMed Web of Science ®Google Scholar
• PiitulainenE, MostafaviB, TanashHA. Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37–40 years. Int J Chron Obstruct Pulmon Dis. 2017;12:495–500. doi:10.2147/COPD28203073
   PubMed Web of Science ®Google Scholar
• LuisettiM, CampoI, ScabiniR, et al. The problems of clinical trials and registries in rare diseases. Respir Med. 2010;104(Suppl 1):S42–S44. doi:10.1016/j.rmed.2010.03.01620413285
   PubMed Web of Science ®Google Scholar
• The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med. 1998;158(1):49–59. doi:10.1164/ajrccm.158.1.97120179655706
   PubMed Web of Science ®Google Scholar
• DawkinsPA, DowsonLJ, GuestPJ, StockleyRA. Predictors of mortality in alpha1-antitrypsin deficiency. Thorax. 2003;58(12):1020–1026. doi:10.1136/thorax.58.12.102014645964
   PubMed Web of Science ®Google Scholar
• GreenCE, ParrDG, EdgarRG, StockleyRA, TurnerAM. Lung density associates with survival in alpha 1 antitrypsin deficient patients. Respir Med. 2016;112:81–87. doi:10.1016/j.rmed.2016.01.00726874894
   PubMed Web of Science ®Google Scholar
• StockleyRA, LuisettiM, MiravitllesM, PiitulainenE, FernandezP, Alpha One International Registry g. Ongoing research in Europe: Alpha one International Registry (AIR) objectives and development. Eur Respir J. 2007;29(3):582–586. doi:10.1183/09031936.0005360617329492
   PubMed Web of Science ®Google Scholar
• TanashHA, NilssonPM, NilssonJA, PiitulainenE. Survival in severe alpha-1-antitrypsin deficiency (PiZZ). Respir Res. 2010;11:44. doi:10.1186/1465-9921-11-4420420704
   PubMed Web of Science ®Google Scholar
• BarkerAF, Iwata-MorganI, OvesonL, RousselR. Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency. Chest. 1997;112(3):607–613. doi:10.1378/chest.112.3.6079315791
   PubMed Web of Science ®Google Scholar
• SoyD, de la RozaC, LaraB, EsquinasC, TorresA, MiravitllesM. Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. Thorax. 2006;61(12):1059–1064. doi:10.1136/thx.2005.05794316928711
   PubMed Web of Science ®Google Scholar
• PiitulainenE, BernspangE, BjorkmanS, BerntorpE. Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin. Eur J Clin Pharmacol. 2003;59(2):151–156. doi:10.1007/s00228-003-0589-z12728289
   PubMed Web of Science ®Google Scholar
• VidalR, BlancoI, CasasF, JardiR, MiravitllesM. Committee on the national registry of individuals with alpha-1 antitrypsin D. [Guidelines for the diagnosis and management of alpha-1 antitrypsin deficiency]. Arch Bronconeumol. 2006;42(12):645–659. doi:10.1157/1309597417178069
   PubMed Web of Science ®Google Scholar
• GauvainC, MornexJF, PisonC, et al. Health-related quality of life in patients with alpha-1 antitrypsin deficiency: the French experience. COPD. 2015;12(Suppl 1):46–51. doi:10.3109/15412555.2015.1022645
   PubMedGoogle Scholar
• ChapmanKR, BurdonJG, PiitulainenE, et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360–368. doi:10.1016/S0140-6736(15)60860-126026936
   PubMed Web of Science ®Google Scholar
• GreulichT, ChlumskyJ, WenckerM, et al. Safety of biweekly alpha1-antitrypsin treatment in the RAPID programme. Eur Respir J. 2018;52:5. doi:10.1183/13993003.00897-2018
   Web of Science ®Google Scholar
• BygumA, AndersenKE, MikkelsenCS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol. 2009;19(2):147–151. doi:10.1684/ejd.2008.060319264579
   PubMed Web of Science ®Google Scholar
• AlphaNet. Available from: https://www.alphanet.org. Accessed 710, 2019.
   Google Scholar
• SandhausRA, BoydBS. Alpha 1 antitrypsin therapy: a satisfaction survey of individuals self-administering. Am J Respir Crit Care Med. 2018;A46:A1758–A1758.
   Google Scholar
• European Medicines Agency. Respreeza summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/respreeza-epar-product-information_en.pdf. Accessed 710, 2019.
   Google Scholar